CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

To compile our list of the best short squeeze stocks, we made use of stocks screeners to note down stocks with significant ...

Highlighting 10 innovative late-stage BioPharma drugs with the potential to reshape treatment paradigms and industry dynamics ...

ARK also increased its position in CoreWeave Inc (CRWV) by purchasing 10,308 shares through its ARKK ETF, valued at $734,857, and made smaller acquisitions in CRISPR Therapeutics AG (NASDAQ:CRSP), ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the most oversold biotech stocks to invest in. Following the company’s third-quarter financial results, Oppenheimer reaffirmed its Outperform rating ...